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A striking feature of severe forms of coronavirus disease 2019 (COVID-19), the current pandemic 38 
caused by the coronavirus SARS-CoV-2, is severe endothelial injury with micro- and macro-39 
thrombotic disease in the lung and other organs, including the heart. This has led to speculation that 40 
viral infection may damage the endothelium through two mechanisms: indirectly, via neighbourhood 41 
effects, circulating mediators and immune mechanisms, or directly by viral infection of endothelial 42 
cells (EC).  43 
To support the hypothesis of direct viral damage of EC via virus-induced infection, the cells should 44 
express the main receptor for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2), a 45 
metalloproteinase component of the renin-angiotensin hormone system and a critical regulator of 46 
cardiovascular homeostasis1. Indeed, several recent review articles propose that SARS-CoV-2 binding 47 
to ACE2 on EC is the mechanism through which the virus may cause direct endothelial damage and 48 
endothelialitis1. However, expression of ACE2 in EC has not been convincingly demonstrated to 49 
support this assumption, nor has there been sufficient evidence to support a direct infection of EC by 50 
SARS-CoV-2.  51 
To address the questions of ACE2 expression in human EC and of the ability of SARS-CoV-2 to infect 52 
the endothelium, we interrogated transcriptomic and epigenomic data on human EC and studied the 53 
interaction and replication of SARS-Cov-2 and its viral proteins with EC in vitro. Analysis of RNA-seq 54 
was carried out on ENCODE# data from EC from arterial, venous and microvascular beds, in 55 
comparison with epithelial cells from respiratory, gastrointestinal and skin sources. Very low or no 56 
basal ACE2 expression was found in EC, compared to epithelial cells (Figure A-B). Moreover, in vitro 57 
exposure of EC to inflammatory cytokines reported as elevated in the plasma of patients with severe 58 
COVID-19 failed to upregulate ACE2 expression (Figure C).  59 
Single-cell RNA-sequencing (scRNAseq) of human organ donor hearts2 showed that while ACE2 60 
sequence reads are abundant in pericytes (PC), they are rare in EC (Figure D). Out of 100,579 EC, 61 












































    
    



















This could reflect true low and rare endothelial ACE2 expression, but also contamination from 63 
adherent PC fragments, a common confounder in vascular scRNAseq data3. If such fragments 64 
contributed the ACE2 transcripts observed in certain EC, we would expect to detect other pericyte 65 
transcripts in the same cells. Indeed, among the top-50 gene transcripts enriched in ACE2+ vs. ACE2- 66 
EC, we noticed several known pericyte markers, including PDGFRB, ABCC9, KCNJ8 and RGS5 (Figure 67 
E). Comparison of transcript abundance across the three major vascular and mesothelial cells 68 
showed that the top-50 gene transcripts were expressed at the highest levels in PC (Figure E). This 69 
suggests that the rare occurrence of ACE2 transcripts in human heart EC is likely caused by pericyte 70 
contamination. Similar conclusions have previously been reached in mouse tissues3 . 71 
Analysis of the chromatin landscape at the ACE2 gene locus in human umbilical vein EC (HUVEC) 72 
using data from ENCODE further supports this concept. The histone modification mark H3K27me3, 73 
which indicates repressed chromatin, was enriched at the ACE2 transcription start site (TSS); 74 
conversely, promoter, enhancer and gene body activation marks (H3K27ac, H3K4me1, H3K4me2, 75 
H3K4me3, H3K36me3), RNA polymerase-II and DNase I hypersensitivity were absent or low, 76 
suggesting that ACE2 is inactive in EC. In marked contrast, the adjacent gene BMX, an endothelial-77 
restricted non-receptor tyrosine ki ase displays an epigenetic profile consistent with active 78 
endothelial expression (Figure F). Thus, transcriptomic and epigenomic data indicate that ACE2 is not 79 
expressed in human EC.  80 
Other cell surface molecules have been suggested as possible receptors for the virus, but their role 81 
in supporti g SARS-CoV-2 cell infection remains to be demonstrated. We therefore tested directly 82 
whether EC could be capable of supporting coronavirus replication in vitro. Productive levels of 83 
replication in primary human cardiac and pulmonary EC were observed for the human coronavirus 84 
229E GFP reporter virus4, which utilises CD13 as its receptor, demonstrating directly that human EC 85 
can support coronavirus replication in principle (Figure G). However, when cells were exposed to 86 












































    
    



















concentrations of virus compared to more permissive VeroE6 cells (Figure H). The observed low 88 
levels of SARS-CoV-2 replication in EC are likely explained by viral entry via a non-ACE2 dependent 89 
route, due to exposure to extremely high concentrations of virus in these experiments (MOI 10 and 90 
100).  91 
These data indicate that direct endothelial infection by SARS-Cov-2 is not likely to occur. The 92 
endothelial damage reported in severely ill COVID19 patients is more likely secondary to infection of 93 
neighbouring cells and/or other mechanisms, including immune cells, platelets and complement 94 
activation, and circulating proinflammatory cytokines. Our hypothesis is corroborated by recent 95 
evidence that plasma from critically ill and convalescent patients with COVID-19 causes endothelial 96 
cell cytotoxicity5. These finding have implications for therapeutic approaches to tackle vascular 97 
damage in severe COVID19 disease.   98 
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 150 
Figure Legend 151 
Figure: Analysis of ACE2 expression in human endothelial cells and of coronavirus replication in 152 
primary human endothelial cells.  153 
(A-B) Comparison of ACE2 expression in human primary epithelial and endothelial cells using total 154 
RNA-seq data from the ENCODE Database shows low or absent expression in EC. (A) The difference 155 
of ACE2 expression in epithelial and endothelial cells is shown in boxplots with individual, as well as 156 
grouped samples (inner boxplot). Each dot represents a single sample (n=2 per cell type). (B) 157 
Transcriptome profiles of epithelial and endothelial cells are shown in a density plot, using the 158 
median of all samples per group (n=19360 genes). ACE2 expression in each group is marked with a 159 
dotted line: ACE2 expression in endothelial cells (red) overlaps with the peak for non-expressed 160 












































    
    



















indicating detectable expression. Median ACE2 expression in endothelial cells equals -5.6 in log2 162 
CPM (Counts Per Million), which corresponds to 0 raw read counts, signifying undetectable ACE2 163 
expression in the majority of endothelial cells. Expression values in all plots are represented as log2-164 
transformed CPM, normalized by Trimmed Mean of M-value (blue: epithelial, red: endothelial). (C) 165 
ACE2 expression is not regulated by inflammatory cytokines in HUVEC. qPCR analysis of ACE2 166 
mRNA expression in HUVEC treated with a mix of 4 cytokines/chemokines (TNF-α, IL1-β, IL8 and 167 
IL6/IL6R chimeric protein) for 4h or 24h at 0, 0.01, 0.1 or 1.0 ng/ml. Data are normalized to GAPDH 168 
and presented as mean ± SEM of 3 independent experiments. (D-E) Very low-level, rare and likely 169 
contaminating ACE2 transcripts are seen in EC. (D) ACE2 transcript reads are detected preferentially 170 
in PC. UMAP landscapes of publicly available human heart datasets2 include 100,579 endothelial 171 
cells (EC), 77,856 pericytes (PC), 16,242 smooth muscle cells (SMC) and 718 mesothelial cells (MC) 172 
(https://www.heartcellatlas.org/). ACE2 transcript reads are detected preferentially in the PC cluster 173 
(enriching for ABCC9) and are rare in the EC cluster (enriching for PECAM1). (E) PC transcripts are 174 
enriched together with ACE2 in 0.47% of EC. Dot plot displaying the abundance of top-50 transcripts 175 
enriched ACE2+ vs. ACE2- EC, across cell types indicated in D.  (The Wilcoxon Rank Sum tests with 176 
Bonferroni-corrected p values are < 1E-60 for each). (F) Epigenetic profiling indicates that the ACE2 177 
gene is inactive in EC. ChIP-seq bindi g profiles in HUVEC for histone modifications, RNA Pol2 178 
enrichment and DNAse I hypersensitivity. The x axis represents the genomic position, the 179 
transcription start sites are indicated by closed arrows and the direction of transcription is indicated 180 
by open arrows; the y axis shows ChIP-seq signal in reads per million per base pair (rpm/bp). The 181 
bottom row represents the chromatin state segmentation. Colour key: active promoter, red; 182 
enhancers, yellow; transcriptional elongation, green; repressed, grey. (G-H) Coronavirus replication 183 
in primary human cardiac and pulmonary endothelial cells shows limited replication of SARS-CoV-184 
2. (G) Viral replication curves in human pulmonary (HPAEC) and cardiac (HCAEC) endothelial cells 185 
following infection with control HCoV-229E GFP reporter virus (MOI = 0.6). Virus replication was 186 












































    
    



















technical replicates are shown at each time point for each biological replicate. (H) Viral growth 188 
curves in HPAEC (n=3), HCAEC (n=3), and non-endothelial Vero cells (n=1) following infection with 189 
SARS-CoV-2 at MOI = 10 or 100. Supernatant were collected at 1, 24, and 48 hours post infection and 190 
virus copy number quantified by RT-qPCR detection of the SARS-CoV-2 N3 gene. TCID= tissue culture 191 
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